BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31235732)

  • 1. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
    Wang T; Hao D; Yang S; Ma J; Yang W; Zhu Y; Weng M; An X; Wang X; Li Y; Wu D; Tang J; Yang C; He Y; Zhang L; Jin X; Wang G; Li Z; Zheng T; Meng H; Feng Y; Li X
    Cell Death Dis; 2019 Jun; 10(7):495. PubMed ID: 31235732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
    Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
    Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
    Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
    Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
    Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
    Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27.
    Jiang J; Xie C; Liu Y; Shi Q; Chen Y
    Biomed Pharmacother; 2019 Jan; 109():595-601. PubMed ID: 30399596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-128/homeobox B8 axis regulates ovarian cancer cell progression.
    Li R; Gong L; Li P; Wang J; Bi L
    Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):499-507. PubMed ID: 31271703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.
    Zou YT; Gao JY; Wang HL; Wang Y; Wang H; Li PL
    Genet Mol Res; 2015 Jul; 14(3):8766-77. PubMed ID: 26345808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
    Qiu PY; Deng XH; Li L
    Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells.
    Wu J; Sun Y; Zhang PY; Qian M; Zhang H; Chen X; Ma D; Xu Y; Chen X; Tang KF
    Cell Death Dis; 2016 Sep; 7(9):e2384. PubMed ID: 27685628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y; Huang S; Guo Y; Li L
    Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of miRNAs is associated with tumour genome instability and predicts the outcome of ovarian cancer patients treated with platinum agents.
    Wang T; Wang G; Zhang X; Wu D; Yang L; Wang G; Hao D
    Sci Rep; 2017 Nov; 7(1):14736. PubMed ID: 29116111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
    Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
    Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
    Walker TDJ; Faraahi ZF; Price MJ; Hawarden A; Waddell CA; Russell B; Jones DM; McCormick A; Gavrielides N; Tyagi S; Woodhouse LC; Whalley B; Roberts C; Crosbie EJ; Edmondson RJ
    Br J Cancer; 2023 May; 128(9):1765-1776. PubMed ID: 36810910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
    Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
    Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
    Ziebarth AJ; Nowsheen S; Steg AD; Shah MM; Katre AA; Dobbin ZC; Han HD; Lopez-Berestein G; Sood AK; Conner M; Yang ES; Landen CN
    Clin Cancer Res; 2013 Jan; 19(1):170-82. PubMed ID: 23147994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.